Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139903 | 0.94 | HRH3 (0.52) | HRH3SMN1; SMN2ALDH1A1KDM4EMAOA | |
| SCHEMBL26819652 | 0.84 | KDM1A (0.47) | HRH3SMN1; SMN2ALDH1A1MAOAMAOB | |
| SCHEMBL833489 | 0.84 | ALDH1A1 (0.58) | SMN1; SMN2ALDH1A1KDM4ECYP2A6PTPN1 | |
| SCHEMBL22708340 | 0.83 | HRH3 (0.58) | HRH3SMN1; SMN2MAOAMAOBMAPT | |
| SCHEMBL11912880 | 0.83 | ALDH1A1 (0.47) | HRH3SMN1; SMN2ALDH1A1KDM4ECYP2A6 | |
| SCHEMBL4129194 | 0.83 | HTT (0.49) | HRH3SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL15119426 | 0.83 | ALDH1A1 (0.50) | HRH3SMN1; SMN2ALDH1A1KDM4ECYP2A6 | |
| SCHEMBL5207844 | 0.83 | HRH3 (0.61) | HRH3 | |
| SCHEMBL3636729 | 0.82 | ALDH1A1 (0.56) | SMN1; SMN2ALDH1A1KDM4ECYP2A6PTPN1 | |
| SCHEMBL2000967 | 0.82 | HRH3 (0.52) | HRH3ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1568690-A1 | The use of carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones as sodium channel blockers | Euro-Celtique S.A. (LU) | 2005-08-31 | — | — | EP | claimed |
| EP-0986540-B1 | THE USE OF CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AS SODIUM CHANNEL BLOCKERS | EURO CELTIQUE SA (LU) | 2005-02-16 | — | — | EP | claimed |
| US-6696442-B2 | THERAPY OF DISORDER RESPONSIVE TO THE BLOCKADE OF SODIUM CHANNELS IN A MAMMAL SUFFERING THEREFROM BY ADMINISTERING CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES, WHICH ACT AS BLOCKERS OF SODIUM CHANNELS | EURO-CELTIQUE S.A. (LU) | 2004-02-24 | — | — | US | claimed |
| US-20030225080-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | EURO-CELTIQUES S.A. | 2003-12-04 | — | — | US | claimed |
| US-6613803-B1 | Treating, preventing or ameliorating pain | EURO-CELTIQUE S.A. (LU) | 2003-09-02 | — | — | US | claimed |
| US-20020183321-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | COCENSYS, INC. | 2002-12-05 | — | — | US | claimed |
| US-20020061886-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | COCENSYS, INC. | 2002-05-23 | — | — | US | claimed |
| JP-2001526648-A | — | — | 2001-12-18 | — | — | JP | claimed |
| EP-0986540-A4 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | COCENSYS INC (US) | 2001-07-11 | — | — | EP | claimed |
| EP-0986540-A1 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | Cocensys, Inc. (US) | 2000-03-22 | — | — | EP | claimed |
| WO-1998047869-A1 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | COCENSYS, INC. (US) | 1998-10-29 | — | — | WO | claimed |
| WO-2023217201-A2 | NOVEL PYRIMIDO-HETEROCYCLIC NOVEL COMPOUND SERVING AS WEE1 INHIBITOR AND APPLICATION THEREOF | 杭州德睿智药科技有限公司 | 2023-11-16 | — | — | WO | disclosed |
| EP-2266987-B1 | Substituted pyrrolo-pyrazole derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES SRL (IT) | 2017-05-17 | — | — | EP | disclosed |
| US-9238656-B2 | Imidazo[4,5-b]pyridine derivatives as ALK and JAK modulators for the treatment of proliferative disorders | CEPHALON, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| EP-2809671-B1 | IMIDAZO [4, 5 - B]PYRIDINE DERIVATIVES AS ALK AND JAK MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CEPHALON INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20020183321-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | COCENSYS, INC. | 2002-12-05 | — | — | US | disclosed |
| US-20020061886-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | COCENSYS, INC. | 2002-05-23 | — | — | US | disclosed |
| EP-0986540-A4 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | COCENSYS INC (US) | 2001-07-11 | — | — | EP | disclosed |
| EP-0986540-A1 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | Cocensys, Inc. (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998047869-A1 | CARBOCYCLIC AND HETEROCYCLIC SUBSTITUTED SEMICARBAZONES AND THIOSEMICARBAZONES AND THE USE THEREOF | COCENSYS, INC. (US) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225080-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | GLRB, SLC1A1, SOD1 | HRH3 240/4885SMN1; SMN2 87/4885ALDH1A1 91/4885 |
| US-20020061886-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | GLRB, SLC1A1, SOD1 | HRH3 240/4885SMN1; SMN2 87/4885ALDH1A1 91/4885 |
| US-20020183321-A1 | Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof | GLRB, CBR1, ALDH1A2 | HRH3 167/4885SMN1; SMN2 78/4885ALDH1A1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.